Akero Therapeutics

Akero Therapeutics

CA - South SF
Biotechnology
WebsiteLinkedInCareers Page

Focus: NASH therapy

Akero Therapeutics is a life sciences company focused on NASH therapy.

Metabolic Diseases
Open Jobs
0

Pipeline & Clinical Trials

Phase 2
Clinical Trials (1)
NCT04767529A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
Phase 2
Phase 2
Clinical Trials (1)
NCT05039450A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
Phase 2
Phase 2
Clinical Trials (1)
NCT03976401A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
Phase 2
Efruxifermin
NASH/MASH
Phase 3
Clinical Trials (1)
NCT06161571A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Phase 3
Phase 3
Clinical Trials (1)
NCT06528314A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Phase 3
Efruxifermin
NASH With Fibrosis
Phase 3
Clinical Trials (1)
NCT06215716A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 6 clinical trials